Abstract:According to the latest cancer research data, there are a significant number of new cancer cases and a substantial mortality rate each year. Although a substantial number of clinical patients are treated with existing cancer drugs each year, the efficacy is unsatisfactory. The incidence is still high and the effectiveness of most cancer drugs remains unsatisfactory. Therefore, we evaluated the human proteins for their causal relationship to for cancer risk and therefore also their potential as drug targets. We used summary tumors data from the FinnGen and cis protein quantitative trait loci (cis-pQTL) data from a genome-wide association study, and employed Mendelian randomization (MR) to explore the association between potential drug targets and nine tumors, including breast, colorectal, lung, liver, bladder, prostate, kidney, head and neck, pancreatic caners. Furthermore, we conducted MR analysis on external cohort. Moreover, Bidirectional MR, Steiger filtering, and colocalization were employed to validate the main results. The DrugBank database was used to discover potential drugs of tumors. Under the threshold of False discovery rate (FDR) < 0.05, results showed that S100A16 was protective protein and S100A14 was risk protein for human epidermal growth factor receptor 2-positive (HER-positive) breast cancer, phosphodiesterase 5A (PDE5A) was risk protein for colorectal cancer, and melanoma inhibitory activity (MIA) was protective protein for non-small cell lung carcinoma (NSCLC). And there was no reverse causal association between them. Colocalization analysis showed that S100A14 (PP.H4.abf = 0.920) and S100A16 (PP.H4.abf = 0.932) shared causal variation with HER-positive breast cancer, and PDE5A (PP.H4.abf = 0.857) shared causal variation with colorectal cancer (CRC). The MR results of all pQTL of PDE5A and MIA were consistent with main results. In addition, the MR results of MIA and external outcome cohort were consistent with main results. In this study, genetic predictions indicate that circulating S100 calcium binding protein A14 (S100A14) and S100 calcium binding protein A16 (S100A16) are associated with increase and decrease in the risk of HER-positive breast cancer, respectively. Circulating PDE5A is associated with increased risk of CRC, while circulating MIA is associated with decreased risk of NSCLC. These findings suggest that four proteins may serve as biomarkers for cancer prevention and as potential drug targets that could be expected for approval.

Therapeutic Targets for Colorectal Cancer: Proteome-Wide and Genome-Wide Mendelian Randomization and Colocalization Analyses

Multi-omics Analysis to Identify Susceptibility Genes for Colorectal Cancer.

Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome

Cross-cancer pleiotropic analysis identifies three novel genetic risk loci for colorectal cancer

Proteome-wide analysis reveals potential therapeutic targets for Colorectal cancer: a two-sample mendelian randomization study

Therapeutic Strategy on Peripheral Treg Cell and DN T Cell for Colorectal Cancer Based on Mendelian Randomization

Integrating plasma proteome with genome reveals novel protein biomarkers in colorectal cancer

Identification of Potential Functional Variants and Genes at 18q21.1 Associated with the Carcinogenesis of Colorectal Cancer.

Potential drug targets for tumors identified through Mendelian randomization analysis

Identifying therapeutic targets for breast cancer: insights from systematic Mendelian randomization analysis

Integrating Proteomics and Transcriptomics for the Identification of Potential Targets in Early Colorectal Cancer

PSMC2 and CXCL8-Modulated Four Critical Gene Biomarkers and Druggable and Vaccinable Targets for Colorectal Cancer

Therapeutic targets for hepatocellular carcinoma identified using proteomics and Mendelian randomization

Novel Common Target Genes for Breast Cancer and Colorectal Cancer: A Mendelian Randomization and Spatial Transcriptomics Study

Causal relationship between complement C1QB and colorectal cancer: a drug target Mendelian randomization study

Multi-omics profiling combined with molecular docking reveals immune-inflammatory proteins as potential drug targets in colorectal cancer

Clinical-Molecular Characteristics and Post-Translational Modifications of Colorectal Cancer in North China: Implications for Future Targeted Therapies

Integrated Proteomic and Phosphoproteomic Analysis for Characterization of Colorectal Cancer

Genome-Wide Association and Transcriptome-Wide Association Studies Identify Novel Susceptibility Genes Contributing to Colorectal Cancer

Applying Proteomics Integrated With Gene Microarray for Discovery of Colorectal Cancer Novel Biomarkers

Systematic Investigation of Genetically Determined Plasma and Urinary Metabolites to Discover Potential Interventional Targets for Colorectal Cancer.